Inhibitors for urokinase receptor
    6.
    发明授权
    Inhibitors for urokinase receptor 失效
    尿激酶受体抑制剂

    公开(公告)号:US06528619B1

    公开(公告)日:2003-03-04

    申请号:US09402641

    申请日:2000-01-10

    IPC分类号: C07K708

    CPC分类号: C12N9/6462 C12Y304/21073

    摘要: The present invention provides peptides as inhibitors of the binding of urokinase to the urokinase receptor. The peptides have the general structural formula (I): X1-[X2]n-X3-X4-K-Y-F-X5-X6-I-X7-W-[X8]m  (I) in which X1, X2, X3, X4, X5, X6, X7 and X8 each denote an aminocarboxylic acid, n and m are each independently 0 or 1, K denotes an aminocarboxylic acid with a lysine side chain, Y denotes an aminocarboxylic acid with a tyrosine side chain, F denotes an aminocarboxylic acid with a phenyl-alanine side chain, I denotes an aminocarboxylic acid with an isoleucine side chain, W denotes an aminocarboxylic acid with a tryptophan side chain, and the monomeric building blocks are linked by —CONR1— or —NR1CO— bonds where R1 in each case independently denotes hydrogen, methyl or ethyl, and pharmaceutically compatible salts and derivatives thereof.

    摘要翻译: 本发明提供肽作为尿激酶与尿激酶受体结合的抑制剂。 肽具有通式结构式(I):其中X 1,X 2,X 3,X 4,X 5,X 6,X 7和X 8各自表示氨基羧酸,n和m各自独立地为0或1,K表示氨基羧酸, 赖氨酸侧链,Y表示具有酪氨酸侧链的氨基羧酸,F表示具有苯基 - 丙氨酸侧链的氨基羧酸,I表示具有异亮氨酸侧链的氨基羧酸,W表示具有色氨酸侧链的氨基羧酸, 并且单体结构单元通过-CONR1-或-NR1CO-键连接,其中R 1在每种情况下独立地表示氢,甲基或乙基,以及其药学上相容的盐和衍生物。

    SMALL PEPTIDIC AND PEPTIDO-MIMETIC AFFINITY LIGANDS FOR FACTOR VIII AND FACTOR VIII-LIKE PROTEINS
    8.
    发明申请
    SMALL PEPTIDIC AND PEPTIDO-MIMETIC AFFINITY LIGANDS FOR FACTOR VIII AND FACTOR VIII-LIKE PROTEINS 审中-公开
    用于因子VIII和因子VIII样蛋白的小肽和肽 - 亲和力配体

    公开(公告)号:US20090215025A1

    公开(公告)日:2009-08-27

    申请号:US12096503

    申请日:2006-12-07

    摘要: The present invention pertains to compounds that show a high affinity to Factor VIII and Factor VIII-like proteins, and their uses. The compounds are characterized by the general Formula B-Q-X, wherein B represents a dipeptide, tripeptide, or a peptidomimetic; Q represents a spacer and X represents an anchoring molecule; Q and X are optional. These compounds can be used for coating a solid support material. The resulting coated solid support material can be used for purifying Factor VIII by means of affinity chromatography methods. In addition, the compounds of the present invention may be used for stabilizing Factor VIII and for enhancing its activity. The present invention thus pertains also to methods for manufacturing a stabilized Factor VIII containing medicament of increased activity. The inventive compounds can furthermore be used in diagnostic kits and as research tools.

    摘要翻译: 本发明涉及对因子VIII和因子VIII样蛋白表现出高亲和力的化合物及其用途。 该化合物的特征在于通式B-Q-X,其中B代表二肽,三肽或拟肽; Q表示间隔基,X表示锚定分子; Q和X是可选的。 这些化合物可用于涂覆固体支持材料。 所得的包被的固体支持物质可用于通过亲和层析方法纯化因子VIII。 此外,本发明的化合物可用于稳定因子VIII并提高其活性。 因此,本发明也涉及制备具有增加的活性的含有稳定因子VIII的药物的方法。 本发明化合物还可用于诊断试剂盒和研究工具。

    Peptide and peptide mimetic derivatives with integrin-inhibitors properties II
    9.
    发明授权
    Peptide and peptide mimetic derivatives with integrin-inhibitors properties II 有权
    具有整合蛋白抑制剂性质的肽和肽模拟衍生物II

    公开(公告)号:US07276482B2

    公开(公告)日:2007-10-02

    申请号:US10344668

    申请日:2001-08-02

    IPC分类号: A61K38/10

    摘要: The invention relates to compounds of formula (I) B-Q-X1, wherein B is a bioactive, cell adhesive mediating molecule, selected from the group (i) and Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (SEQ ID NO: 1) (ii), Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (SEQ ID NO: 2) (iii), Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (SEQ ID NO: 3) (iv), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg (SEQ ID NO: 4) (v), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn (SEQ ID NO: 5) (vi), Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg (SEQ ID NO: 6) (vii), wherein (i) X, Y, Z, R2, R3, R4, A, Ar, Hal, Het, Het1, n, m, o, p, q, s, t have the meanings cited in claim 1, Q is absent or is an organic spacer molecule, X1 is an anchor molecule selected from the group cited in claim 1, and the salts thereof, which can be used as integrin inhibitors particularly for treatment of illness, deficiencies and inflammations caused by implants and osteolytic illnesses such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis, in addition to the acceleration and strengthening of the integration process of implants or the biocompatible surface in tissue.

    摘要翻译: 本发明涉及式(I)BQX 1的化合物,其中B是选自(i)和Thr-Trp-Tyr-Lys-Ile-Ala的生物活性的细胞粘附介导分子 -Ph-Gln-Arg-Asn-Arg-Lys(SEQ ID NO:1)(ii),Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys(SEQ ID NO: )(iii),Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys(SEQ ID NO:3)(iv),Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln -Arg-Asn-Arg(SEQ ID NO:4)(v),Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn(SEQ ID NO:5)(vi) -Tyr-Lys-Ile-Ala-Phe-Gln-Arg(SEQ ID NO:6)(vii),其中(i)X,Y,Z,R 2,R 3 A,Ar,Hal,Het,Het 1,n,m,o,p,q,s,t具有引用的含义 在权利要求1中,Q不存在或是有机间隔分子,X 1是选自权利要求1所述的基团的锚定分子及其盐,其可以用作整联蛋白抑制剂,特别是用于 治疗由植入物和溶骨性疾病引起的疾病,缺陷和炎症 例如骨质疏松症,血栓形成,心肌梗死和动脉硬化,以及植入物或组织中生物相容性表面的整合过程的加速和加强。

    Cyclic adhesion inhibitors
    10.
    发明授权
    Cyclic adhesion inhibitors 失效
    环状粘连抑制剂

    公开(公告)号:US6001961A

    公开(公告)日:1999-12-14

    申请号:US694387

    申请日:1996-09-16

    CPC分类号: C07K7/64 A61K38/00

    摘要: The invention relates to novel cyclopeptides of the formula Icyclo-(nArg-nGly-nAsp-nD-nE) I,in whichD and E in each case independently of one another are Gly, Ala, .beta.-Ala, Asn, Asp, Asp(OR), Arg, Cha, Cys, Gln, Glu, His, Ile, Leu, Lys, Lys(Ac), Lys(AcNH.sub.2), Lys(AcSH), Met, Nal, Nle, Orn, Phe, 4-Hal-Phe, homo-Phe, Phg, Pro, Pya, Ser, Thr, Tia, Tic, Trp, Tyr or Val, which amino acid residues can also be derivatized,R is alkyl having 1-18 carbon atoms,Hal is F, Cl, Br, I,Ac is alkanoyl having 1-10 carbon atoms, aroyl having 7-11 carbon atoms or aralkanoyl having 8-12 carbon atoms,n denotes no substituent or an alkyl radical R, benzyl or an aralkyl radical having 7-18 carbon atoms on the alpha-amino function of the relevant amino acid residue,with the proviso that at least one amino acid residue has a substituent n and that, where residues of optically active amino acids and amino acid derivatives are involved, both the D and the L forms are included, and also their physiologically acceptable salts.These compounds act as integrin inhibitors and can be used in particular for the prophylaxis and treatment of disorders of the circulation, angiogenic disorders, microbial infections and in tumor therapy.

    摘要翻译: 本发明涉及式I环 - (nArg-nGly-nAsp-nD-nE)I的新型环肽,其中D和E各自独立地为Gly,Ala,β-Ala,Asn,Asp,Asp (OR),Arg,Cha,Cys,Gln,Glu,His,Ile,Leu,Lys,Lys(Ac),Lys(AcNH 2),Lys(AcSH),Met,Nal,Nle,Orn, -Phe,Phe-Phe,Phg,Pro,Pya,Ser,Thr,Tia,Tic,Trp,Tyr或Val,该氨基酸残基也可被衍生化,R是具有1-18个碳原子的烷基,Hal是F, Cl,Br,I,Ac是具有1-10个碳原子的烷酰基,具有7-11个碳原子的芳酰基或具有8-12个碳原子的芳烷酰基,n表示没有取代基或烷基R,苄基或具有7- 相关氨基酸残基的α-氨基官能团上的18个碳原子,条件是至少一个氨基酸残基具有取代基n,并且当涉及光学活性氨基酸和氨基酸衍生物的残基时,D 并且包括L形式,也包括它们的生理学 可接受的盐。 这些化合物用作整联蛋白抑制剂,特别可用于预防和治疗循环障碍,血管生成障碍,微生物感染和肿瘤治疗。